Nonpeptide Inhibitors of Cathepsin G: Optimization of a Novel β-Ketophosphonic Acid Lead by Structure-Based Drug Design
Citations Over Time
Abstract
The serine protease cathepsin G (EC 3.4.21.20; Cat G), which is stored in the azurophilic granules of neutrophils (polymorphonuclear leukocytes) and released on degranulation, has been implicated in various pathological conditions associated with inflammation. By employing high-throughput screening, we identified beta-ketophosphonic acid 1 as a moderate inhibitor of Cat G (IC(50) = 4.1 microM). We were fortunate to obtain a cocrystal of 1 with Cat G and solve its structure by X-ray crystallography (3.5 A). Structural details from the X-ray analysis of 1.Cat G served as a platform for optimization of this lead compound by structure-based drug design. With the aid of molecular modeling, substituents were attached to the 3-position of the 2-naphthyl ring of 1, which occupies the S1 pocket of Cat G, to provide an extension into the hydrophobic S3 region. Thus, we arrived at analogue 7 with an 80-fold potency improvement over 1 (IC(50) = 53 nM). From these results, it is evident that the beta-ketophosphonic acid unit can form the basis for a novel class of serine protease inhibitors.
Related Papers
- → A distinctive repertoire of cathepsins is expressed by juvenile invasive Fasciola hepatica(2008)94 cited
- → Evolutionary History of Cathepsin L (L-like) Family Genes in Vertebrates(2015)36 cited
- → Genetic and Pharmacologic Alteration of Cathepsin Expression Influences Reovirus Pathogenesis(2009)31 cited
- → Identification and characterization of the lamprey cathepsin genes(2019)9 cited
- → Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity(2023)1 cited